COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2…
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 LONDON, July 17, 2023 (GLOBE NEWSWIRE)…